Guideline Recommendations for Laser and Light‑Based Therapy in Refractory Rosacea

Indications for Laser/Light Therapy

Persistent facial erythema that does not improve with topical brimonidine or oxymetazoline is an indication for laser or intense pulsed light (IPL) treatment according to the Global ROSacea Consensus (ROSCO) panel. 1
Visible facial telangiectasia (superficial red vessels) warrants vascular laser therapy (PDL) or IPL as first‑line options per the ROSCO panel. 2
Transient erythema or flushing that remains uncontrolled despite oral beta‑blockers or doxycycline is a ROSCO‑endorsed indication for pulsed‑dye laser (PDL). 1

Pulsed‑dye laser (PDL) 585–595 nm is the most effective modality for treating superficial red telangiectasia, as recommended by the ROSCO panel. 2
Intense pulsed light (IPL) provides a broad‑spectrum alternative for mixed‑type telangiectasia and concurrent erythema, per ROSCO guidance. 1

IPL is the first‑line laser‑based therapy for diffuse persistent erythema; multiple treatment sessions are typically required to achieve satisfactory improvement. 2
PDL 585–595 nm is also effective for diffuse erythema but may need a greater number of sessions compared with IPL. 1

PDL is specifically listed as the first‑line laser option for transient flushing episodes. 2

Session interval: Treatments are generally scheduled every 4–6 weeks based on clinical practice patterns. 3

Active infection in the treatment area precludes laser or IPL therapy (ROSCO panel). 2

Pregnancy is a relative contraindication for most laser procedures (Praxis Medical Insights). 4
Use of photosensitizing medications without an appropriate wash‑out period (Praxis Medical Insights). 4
Recent sun exposure or tanned skin (Praxis Medical Insights). 5
History of keloid formation (ROSCO panel). 2
Unrealistic patient expectations regarding outcomes (Praxis Medical Insights). 3

Oral doxycycline 40 mg modified‑release daily serves as an anti‑inflammatory dose for persistent erythema when topical agents fail (ROSCO panel). 6
Oral beta‑blockers are recommended for managing transient flushing episodes (ROSCO panel). 1
Combined topical regimen of brimonidine 0.33 % gel in the morning plus oxymetazoline 1 % cream in the evening improves erythema control (Praxis Medical Insights). 5

Encapsulated benzoyl peroxide 5 % cream once daily yields rapid improvement by week 2, with 44–50 % of patients achieving clear or almost clear skin by week 12 (Praxis Medical Insights). 3
Minocycline foam 1.5 % once daily achieves a 52 % Investigator’s Global Assessment (IGA) success rate at 12 weeks (Praxis Medical Insights). 3
Oral isotretinoin is reserved for severe, refractory papulopustular disease (ROSCO panel). 2

Topical ivermectin 1 % cream once daily provides the greatest lesion‑reduction efficacy (≈ 83 % reduction) (Praxis Medical Insights). 5
Add oral doxycycline 40 mg modified‑release daily for anti‑inflammatory effect (Praxis Medical Insights). 4
Add brimonidine 0.33 % gel once daily if erythema persists (Praxis Medical Insights). 5
Introduce IPL or PDL after 12–16 weeks to address residual telangiectasia and erythema (ROSCO panel). 1

Ongoing topical maintenance is essential after laser therapy; up to two‑thirds of patients experience relapse without continued topical agents (Praxis Medical Insights). 3

Flushing treatments lack high‑quality evidence; the ROSCO consensus on laser therapy for transient erythema is based on case reports and expert clinical experience (low‑quality evidence). 7
Telangiectasia management with vascular lasers and IPL is supported by consistent clinical outcomes and is considered high‑efficacy (ROSCO panel). 1